TGF-β1 induced MMP-9 expression in HNSCC cell lines via Smad/MLCK pathway

Biochemical and Biophysical Research Communications

Volumn 371, Issue 4, 2008, Pages 713-718

  Sinpitaksakul, Sariya Nuchanardpanit ^a   Pimkhaokham, Atiphan ^a   Sanchavanakit, Neeracha ^a   Pavasant, Prasit ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

Head and neck squamous cell carcinoma; Matrix metalloproteinase 9; Myosin light chain kinase; Smad; Transforming growth factor 1

Indexed keywords

GELATINASE B; MESSENGER RNA; MYOSIN LIGHT CHAIN KINASE; MYOSIN LIGHT CHAIN KINASE INHIBITOR; PROTEIN INHIBITOR; SB 505124; SMAD PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA1; 1,3 BENZODIOXOLE DERIVATIVE; 2 (5 BENZO(1,3)DIOXOL 5 YL 2 TERT BUTYL 3H IMIDAZOL 4 YL) 6 METHYLPYRIDINE HYDROCHLORIDE; 2-(5-BENZO(1,3)DIOXOL-5-YL-2-TERT-BUTYL-3H-IMIDAZOL-4-YL)-6-METHYLPYRIDINE HYDROCHLORIDE; IMIDAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; SMAD3 PROTEIN, HUMAN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ARTICLE; CARCINOMA CELL; CELL LYSATE; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; SUPERNATANT; DRUG ANTAGONISM; GENETICS; HEAD AND NECK TUMOR; METABOLISM; TUMOR CELL LINE;

BENZODIOXOLES; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; HEAD AND NECK NEOPLASMS; HUMANS; IMIDAZOLES; MATRIX METALLOPROTEINASE 9; MYOSIN-LIGHT-CHAIN KINASE; PYRIDINES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RNA, SMALL INTERFERING; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

EID: 44149115681     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.04.128     Document Type: Article

References (43)

1. Page-McCaw A., Ewald A.J., and Werb Z. Matrix metalloproteinases and the regulation of tissue remodeling. Nat. Rev. Mol. Cell Biol. 8 (2007) 221-233
2. Bergers G., Brekken R., McMahon G., Vu T.H., Itoh T., Tamaki K., Tanzawa K., Thorpe P., Itohara S., Werb Z., and Hanahan D. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol. 10 (2000) 737-744
3. Sheu B.C., Hsu S.M., Ho H.N., Lien H.C., Huang S.C., and Lin R.H. A novel role of metalloproteinase in cancer-mediated immunosuppression. Cancer Res. 61 (2001) 237-242
4. Bourguignon L.Y., Gunja-Smith Z., Iida N., Zhu H.B., Young L.J., Muller W.J., and Cardiff R.D. CD44v (3,8-10) is involved in cytoskeleton-mediated tumor cell migration and matrix metalloproteinase (MMP-9) association in metastatic breast cancer cells. J. Cell. Physiol. 176 (1998) 206-215
5. Itoh T., Tanioka M., Matsuda H., Nishimoto H., Yoshioka T., Suzuki R., and Uehira M. Experimental metastasis is suppressed in MMP-9-deficient mice. Clin. Exp. Metastasis 2 (1999) 177-181
6. Itoh T., Tanioka M., Yoshida H., Yoshioka T., Nishimoto H., and Itohara S. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res. 58 (1998) 1048-1051
7. O-charoenrat P., Modjtahedi H., Rhys-Evans P., Court W.J., Box G.M., and Eccles S.A. Epidermal growth factor-like ligands differentially up-regulate matrix metalloproteinase 9 in head and neck squamous carcinoma cells. Cancer Res. 60 (2000) 1121-1128
8. O-Charoenrat P., Rhys-Evans P., Modjtahedi H., Court W., Box G., and Eccles S. Overexpression of epidermal growth factor receptor in human head and neck squamous carcinoma cell lines correlates with matrix metalloproteinase-expression and in vitro invasion. Int. J. Cancer 86 (2000) 307-317
9. de Vicente J.C., Fresno M.F., Villalain L., Vega J.A., and Hernández Vallejo G. Expression and clinical significance of matrix metalloproteinase-2 and matrix metalloproteinase-9 in oral squamous cell carcinoma. Oral Oncol. 41 (2005) 283-293
10. Jordan R.C., Macabeo-Ong M., Shiboski C.H., Dekker N., Ginzinger D.G., Wong D.T., and Schmidt B.L. Overexpression of matrix metalloproteinase-1 and -9 mRNA is associated with progression of oral dysplasia to cancer. Clin. Cancer Res. 10 (2004) 6460-6465
11. Ruokolainen H., Pääkkö P., and Turpeenniemi-Hujanen T. Expression of matrix metalloproteinase-9 in head and neck squamous cell carcinoma: a potential marker for prognosis. Clin. Cancer Res. 10 (2004) 3110-3116
12. Björklund M., and Koivunen E. Gelatinase-mediated migration and invasion of cancer cells. Biochim. Biophys. Acta 1755 (2005) 37-69
13. Egeblad M., and Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2 (2002) 161-174
14. Chakraborti S., Mandal M., Das S., Mandal A., and Chakraborti T. Regulation of matrix metalloproteinases: an overview. Mol. Cell. Biochem. 253 (2003) 269-285
15. Heider T.R., Lyman S., Schoonhoven R., and Behrns K.E. Ski promotes tumor growth through abrogation of transforming growth factor-β signaling in pancreatic cancer. Ann. Surg. 246 (2007) 61-68
16. Grau A.M., Datta P.K., Zi J., Halder S.K., and Beauchamp R.D. Role of Smad proteins in the regulation of NF-kappaB by TGF-beta in colon cancer cells. Cell. Signal. 18 (2006) 1041-1050
17. Peng H., Shintani S., Kim Y., and Wong D.T. Loss of p12CDK2-AP1 expression in human oral squamous cell carcinoma with disrupted transforming growth factor-beta-Smad signaling pathway. Neoplasia 8 (2006) 1028-1036
18. Tsushima H., Kawata S., Tamura S., Ito N., Shirai Y., Kiso S., Imai Y., Shimomukai H., Nomura Y., Matsuda Y., and Matsuzawa Y. High levels of transforming growth factor beta 1 in patients with colorectal cancer: association with disease progression. Gastroenterology 110 (1996) 375-382
19. Gorsch S.M., Memoli V.A., Stukel T.A., Gold L.I., and Arrick B.A. Immunohistochemical staining for transforming growth factor beta 1 associates with disease progression in human breast cancer. Cancer Res. 52 (1992) 6949-6952
20. Friess H., Yamanaka Y., Büchler M., Ebert M., Beger H.G., Gold L.I., and Korc M. Enhanced expression of transforming growth factor beta isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology 105 (1993) 1846-1856
21. Piek E., Heldin C.H., and Ten Dijke P. Specificity, diversity, and regulation in TGF-beta superfamily signaling. FASEB J. 13 (1999) 2105-2124
22. Sehgal I., and Thompson T.C. Novel regulation of type IV collagenase (matrix metalloproteinase-9 and -2) activities by transforming growth factor-beta1 in human prostate cancer cell lines. Mol. Biol. Cell 10 (1999) 407-416
23. Safina A., Vandette E., and Bakin A.V. ALK5 promotes tumor angiogenesis by upregulating matrix metalloproteinase-9 in tumor cells. Oncogene 26 (2007) 2407-2422
24. Han Y.P., Tuan T.L., Hughes M., Wu H., and Garner W.L. Transforming growth factor-beta and tumor necrosis factor-alpha-mediated induction and proteolytic activation of MMP-9 in human skin. J. Biol. Chem. 276 (2001) 22341-22350
25. Heo D.S., Park J.G., Hata K., Day R., Herberman R.B., and Whiteside T.L. Evaluation of tetrazolium-based semiautomatic colorimetric assay for measurement of human antitumor cytotoxicity. Cancer Res. 50 (1990) 3681-3690
26. Derynck R., Jarrett J.A., Chen E.Y., Eaton D.H., Bell J.R., Assoian R.K., Roberts A.B., Sporn M.B., and Goeddel D.V. Human transforming growth factor-beta complementary DNA sequence and expression in normal and transformed cells. Nature 316 (1985) 701-705
27. Keski-Oja J., Leof E.B., Lyons R.M., Coffey R.J., and Moses H.L. Transforming growth factors and control of neoplastic cell growth. J. Cell. Biochem. 33 (1987) 95-107
28. Teicher B.A. Transforming growth factor-beta and the immune response to malignant disease. Clin. Cancer Res. 13 (2007) 6247-6251
29. Biswas S., Guix M., Rinehart C., Dugger T.C., Chytil A., Moses H.L., Freeman M.L., and Arteaga C.L. Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression. J. Clin. Invest. 117 (2007) 1305-1313
30. Welch D.R., Fabra A., and Nakajima M. Transforming growth factor beta stimulates mammary adenocarcinoma cell invasion and metastatic potential. Proc. Natl. Acad. Sci. USA 87 (1990) 7678-7682
31. Derynck R., and Zhang Y.E. Smad-dependent and Smad-independent pathways in TGF-beta family signaling. Nature 425 (2003) 577-584
32. Meyer-ter-Vehn T., Sieprath S., Katzenberger B., Gebhardt S., Grehn F., and Schlunck G. Contractility as a prerequisite for TGF-beta-induced myofibroblast transdifferentiation in human tenon fibroblasts. Invest. Ophthalmol. Vis. Sci. 47 (2006) 4895-4904
33. Hisataki T., Itoh N., Suzuki K., Takahashi A., Masumori N., Tohse N., Ohmori Y., Yamada S., and Tsukamoto T. Modulation of phenotype of human prostatic stromal cells by transforming growth factor-betas. Prostate 58 (2004) 174-182
34. Yamamoto-Yamaguchi Y., Makishima M., Kanatani Y., Kasukabe T., and Honma Y. Reversible differentiation of human monoblastic leukemia U937 cells by ML-9, an inhibitor of myosin light chain kinase. Exp. Hematol. 24 (1996) 682-689
35. Matsumura F., Totsukawa G., Yamakita Y., and Yamashiro S. Role of myosin light chain phosphorylation in the regulation of cytokinesis. Cell Struct. Funct. 26 (2001) 639-644
36. Betapudi V., Licate L.S., and Egelhoff T.T. Distinct roles of nonmuscle myosin II isoforms in the regulation of MDA-MB-231 breast cancer cell spreading and migration. Cancer Res. 66 (2006) 4725-4733
37. Niggli V., Schmidt M., and Nievergelt A. Differential roles of Rho-kinase and myosin light chain kinase in regulating shape, adhesion, and migration of HT1080 fibrosarcoma cells. Biochem. Biophys. Res. Commun. 343 (2006) 602-608
38. Kaneko K., Satoh K., Masamune A., Satoh A., and Shimosegawa T. Myosin light chain kinase inhibitors can block invasion and adhesion of human pancreatic cancer cell lines. Pancreas 24 (2002) 34-41
39. Gu L.Z., Hu W.Y., Antic N., Mehta R., Turner J.R., and de Lanerolle P. Inhibiting myosin light chain kinase retards the growth of mammary and prostate cancer cells. Eur. J. Cancer 42 (2006) 948-957
40. Minamiya Y., Nakagawa T., Saito H., Matsuzaki I., Taguchi K., Ito M., and Ogawa J. Increased expression of myosin light chain kinase mRNA is related to metastasis in non-small cell lung cancer. Tumour Biol. 26 (2005) 153-157
41. Schnaeker E.M., Ossig R., Ludwig T., Dreier R., Oberleithner H., Wilhelmi M., and Schneider S.W. Microtubule-dependent matrix metalloproteinase-2/matrix metalloproteinase-9 exocytosis: prerequisite in human melanoma cell invasion. Cancer Res. 64 (2004) 8924-8931
42. Samanna V., Ma T., Mak T.W., Rogers M., and Chellaiah M.A. Actin polymerization modulates CD44 surface expression, MMP-9 activation, and osteoclast function. J. Cell. Physiol. 213 (2007) 710-720
43. Chintala S.K., Sawaya R., Aggarwal B.B., Majumder S., Giri D.K., Kyritsis A.P., Gokaslan Z.L., and Rao J.S. Induction of matrix metalloproteinase-9 requires a polymerized actin cytoskeleton in human malignant glioma cells. J. Biol. Chem. 273 (1998) 13545-13551